Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up
Advances in Therapy · 2026-01 · 43 (1) · 165-183
DOI: 10.1007/s12325-025-03415-0 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, online erschienen am 18.11.2025. Verfasst von Marcia Cruz-Correa und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Puerto Rico, and Pan American Center for Oncology Trials, San Juan, Puerto Rico. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BeOne Medicines, Ltd., Universitätsmedizin der Johannes Gutenberg-Universität Mainz.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Tislelizumab + chemotherapy has shown promising results as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC). We present long-term safety and efficacy outcomes from the RATIONALE-305 trial after 3 years of follow-up, focusing on the intent-to-treat (ITT) population and subgroups based on programmed death ligand-1 (PD-L1) expression. METHODS: RATIONALE-305, a randomized, double-blind, placebo-controlled, phase 3 trial conducted across 146 centers in Asia, Europe, and North America (December 2018-February 2024), enrolled 997 adults with human epidermal growth factor receptor 2-negative advanced GC/GEJC, randomized 1:1 to receive tislelizumab + chemotherapy or placebo + chemotherapy. The primary endpoint was overall survival (OS) in patients with PD-L1 Tumor Area Positivity (TAP) score ≥ 5% and the ITT population. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), safety, and tolerability. At 3-year follow-up, 959 (96.2%) patients had discontinued or completed treatment. The minimum follow-up duration was 36.6 months. RESULTS: In all randomized patients (n = 997), 69.4% male and 30.6% female, tislelizumab + chemotherapy improved OS versus placebo + chemotherapy [15.0 months (95% CI 13.6-16.5) vs. 12.9 months (95% CI 12.1-14.1); stratified hazard ratio (HR) 0.79]. Investigator-assessed PFS was also improved [6.9 months (95% CI 5.7-7.2) vs. 6.2 months (95% CI 5.6-6.9); stratified HR 0.79]. The ORR was higher with tislelizumab + chemotherapy. In patients with a PD-L1 TAP score ≥ 5% [n = 546 (54.8%)], similar OS and PFS benefits were observed compared to the ITT population. OS was 16.4 (95% CI 13.6-19.1) months versus 12.8 (95% CI 12.0-14.5) months, stratified HR 0.71 for tislelizumab + chemotherapy versus placebo + chemotherapy, respectively. PFS was 7.2 (95% CI 5.8-8.4) months versus 5.9 (95% CI, 5.6-7.0) months, stratified HR 0.69. No new safety signals were identified. CONCLUSION: Results from RATIONALE-305 continued to show durable and improved efficacy outcomes with tislelizumab + chemotherapy versus placebo + chemotherapy at 3 years in advanced GC/GEJC, supporting PD-L1 as a potential prognostic biomarker. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03777657.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Puerto Rico, and Pan American Center for Oncology Trials, San Juan, Puerto Rico.
- Department of Hemato-Oncology, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
- Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
- Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- Department II of Medical Oncology, Linyi Cancer Hospital, Harbin, China.
ORCID-Profile: Marcia Cruz-Correa, Do-Youn Oh, Ken Kato, Josep Tabernero, Keun-Wook Lee, Hidekazu Hirano, David Spigel, Lucjan Wyrwicz, Roberto Pazo Cid, Rui-Hua Xu
Förderung
- BeOne Medicines, Ltd.
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Zitieren
APA
Cruz-Correa, M., Oh, D. Y., Kato, K., Tabernero, J., Bai, Y., Shi, J., Lee, K. W., Hirano, H., Spigel, D., Wyrwicz, L., Pazo Cid, R., Cubillo Gracián, A., Xu, Y., Sheng, T., Yang, S., Xu, R. H., & Moehler, M. (2026). Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up. Advances in Therapy, 43(1), 165-183. https://doi.org/10.1007/s12325-025-03415-0
Vancouver
Cruz-Correa M, Oh DY, Kato K, Tabernero J, Bai Y, Shi J, et al. Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up. Advances in Therapy. 2026;43(1):165-183. doi:10.1007/s12325-025-03415-0
BibTeX
@article{CruzCorrea2026,
author = {Cruz-Correa, Marcia and Oh, Do-Youn and Kato, Ken and Tabernero, Josep and Bai, Yuxian and Shi, Jianhua and Lee, Keun-Wook and Hirano, Hidekazu and Spigel, David and Wyrwicz, Lucjan and Pazo Cid, Roberto and Cubillo Gracián, Antonio and Xu, Yaling and Sheng, Tao and Yang, Silu and Xu, Rui-Hua and Moehler, Markus},
title = {Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up},
journal = {Advances in Therapy},
year = {2026},
volume = {43},
number = {1},
pages = {165--183},
doi = {10.1007/s12325-025-03415-0}
}
EUVIMED